tbuckley/cabot-search huggingface dataset:
Potential serum protein biomarkers of cancer cachexia, muscle atrophy, and survival in pancreatic ductal adenocarcinoma.
Authors: Miles Cameron, Sarah Judge, Andrew Judge
Journal: Journal of Clinical Oncology (2022)

545 Background: Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of death in the United States. Treatment is difficult and often complicated by the presence of cachexia, a systemic wasting condition affecting most PDAC patients at diagnosis. Skeletal muscle atrophy is a hallmark of cachexia and predicts outcomes after surgery and chemotherapy. In this study, we sought to identify possible serum biomarkers of cachexia, which correlates with changes to lean body mass and survival, using an aptamer-based platform in patients with PDAC. We hypothesize that unique proteins associate with cachexia and survival measures. Methods: Using SomaScan we measured the serum levels of 4,006 proteins in 21 patients with PDAC undergoing curative surgery. Clinical data and anthropometric measurements derived from pre-operative CT imaging were compared to protein levels with Spearman correlational analyses and logistic regression. We then queried DAVID Bioinformatics database to identify enriched functional protein categories. Results: Mean age was 66.9 ± 8.91 years, and mean body-weight loss in the six months preceding diagnosis was 12.6 ± 8.80%. Using consensus guidelines considering percent weight loss and skeletal muscle mass and radiation attenuation, 10 subjects (46.7%) were defined as “cachectic.” We found 241 proteins significantly correlated to Cancer Weight Loss Grade (a composite measure of percent body weight loss and body mass index). High IDUA, CTLA4 and USE1, in particular, predicted the worst weight loss grade with 75% sensitivity and 92% specificity (AUC = 0.8894, odds ratio: 36, p = 0.0068). Four additional proteins significantly correlated with skeletal muscle index (CK-MM, CK-MB, PCOC2 and ADH4) while 13 proteins significantly correlated with muscle radiation attenuation. Lastly, we identified 18 proteins that significantly correlated with survival quartile. Of these, we found that elevated HS6ST2 and DEPP significantly predicted early recurrence and death compared to those with lower levels (medial survival: 177 days v. 850 days, p = 0.0049). Of the correlative proteins, enriched gene ontology terms included signal peptide (28.2), cytokine (6.86), negative regulation of endopeptidase activity (3.39), and immunoglobulin domain (3.24). Conclusions: Cancer cachexia in PDAC and various gastrointestinal malignancies remains a key clinical issue. While there are no definitive biomarkers currently in use to diagnose and manage cachexia preemptively, we present several potential candidates in a small cohort of patients. Ultimately, such assays may better elucidate common cachexia-inducing pathways, a shared spectrum of biomarkers and allow for the development of more specific therapies targeting cachexia.
Elevation of plasma tissue factor along with differential elevation of plasma matrix metalloproteinase-2 (MMP-2) in deep vein thrombosis (DVT) &amp; pulmonary embolism (PE) patients Shaker A. Mousa, Richard Liu, Sayed Taheri. DuPont Pharmaceuticasl Co., Wilmington, DE, Millard Filmore Hospital, Buffalo, NY
Journal: Journal of the American College of Cardiology (2001)
Book Reviews
Authors: L.A. Demers-Desrosiers, K.R. Cohen, R.F.H. Catchlove, R.A. Ramsay, K.R. Cohen, L.A. Demers-Deswsiers, R.F.H. Catchlove, Richard F.H. Catchlove, Ronald Grossarth-Maticek, Dusan T. Kanazir, Hermann Vetter, Miroslav Jankovic, Christa Schreiber, Irmela Florin, Wolfgang Rost, Catherine J. Green, Theodore Millon, Robert B. Meagher, Jr., Stuart Shipko, William A. Alvarez, Nicholas Noviello
Journal: Psychotherapy and Psychosomatics (1983)
Chronic exposure to high glucose conditions regulate the activation and expression of inflammatory genes in human vascular endothelial cells Bobby V. Khan, Sushant R. Navalkar, Rama Natarajan, Qamar A. Khan, Sampath Parthasarathy. Emory University School of Medicine, Atlanta, GA, Atlanta Vascular Research Institute, Atlanta, GA
Journal: Journal of the American College of Cardiology (2001)
Flexible Optogenetic Transducer Device for Remote Neuron Modulation Using Highly Upconversion‐Efficient Dendrite‐Like Gold Inverse Opaline Structure
Authors: Chao‐Yi Chu, Pu‐Wei Wu, Jung‐Chih Chen, Nien‐Ti Tsou, You‐Yi Lin, Yu‐Chun Lo, Ssu‐Ju Li, Ching‐Wen Chang, Bo‐Wei Chen, Chia‐Lin Tsai, You‐Yin Chen, Ta‐Chung Liu, San‐Yuan Chen
Journal: Advanced Healthcare Materials (2021)

A remote optogenetic device for analyzing freely moving animals has attracted extensive attention in optogenetic engineering. In particular, for peripheral nerve regions, a flexible device is needed to endure the continuous bending movements of these areas. Here, a remote optogenetic optical transducer device made from a gold inverse opaline skeleton grown with a dendrite-like gold nanostructure (D-GIOF) and chemically grafted with upconversion nanoparticles (UCNPs) is developed. This implantable D-GIOF-based transducer device can achieve synergistic interaction of the photonic crystal effect and localized surface plasmon resonance, resulting in considerable UCNP conversion efficiency with a negligible thermal effect under low-intensity 980 nm near-infrared (NIR) light excitation. Furthermore, the D-GIOF-based transducer device exhibits remarkable emission power retention (≈100%) under different bending states, indicating its potential for realizing peripheral nerve stimulation. Finally, the D-GIOF-based transducer device successfully stimulates neuronal activities of the sciatic nerve in mice. This study demonstrates the potential of the implantable device to promote remote NIR stimulation for modulation of neural activity in peripheral nerve regions and provides proof of concept for its in vivo application in optogenetic engineering.
Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study
Authors: Lingfang Xia, Jin Peng, Ge Lou, Mei Pan, Qi Zhou, Wenjing Hu, Huirong Shi, Li Wang, Yunong Gao, Jianqing Zhu, Yu Zhang, Rong Sun, Xianfeng Zhou, Quanren Wang, Xiaohua Wu
Journal: Journal for ImmunoTherapy of Cancer (2022)

Background Combination treatments with immune-checkpoint inhibitor and antiangiogenic therapy have the potential for synergistic activity through modulation of the microenvironment and represent a notable therapeutic strategy in recurrent ovarian cancer (ROC). We report the results of camrelizumab (an anti-programmed cell death protein-1 antibody) in combination with famitinib (a receptor tyrosine kinase inhibitor) for the treatment of platinum-resistant ROC from an open-label, multicenter, phase 2 basket trial. Methods Eligible patients with platinum-resistant ROC were enrolled to receive camrelizumab (200 mg every 3 weeks by intravenous infusion) and oral famitinib (20 mg once daily). All patients had disease progression during or &lt;6 months after their most recent platinum-based chemotherapy. Primary endpoint was confirmed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) V.1.1 based on investigator’s assessment. Secondary endpoints included disease control rate (DCR), duration of response (DoR), time to response (TTR), progression-free survival (PFS), overall survival (OS), 12-month OS rate and safety profile. Results Of the 37 women enrolled, 11 (29.7%) patients had primary platinum resistant, 15 (40.5%) patients had secondary platinum resistant and 11 (29.7%) patients had primary platinum refractory disease. As the cut-off date of April 9, 2021, nine (24.3%) patients had achieved a confirmed objective response, the ORR was 24.3% (95% CI, 11.8 to 41.2) and the DCR was 54.1% (95% CI, 36.9 to 70.5). Patients with this combination regimen showed a median TTR of 2.1 months (range, 1.8–4.1) and a median DoR of 4.1 months (95% CI, 1.9 to 6.3). Median PFS was 4.1 months (95% CI, 2.1 to 5.7), and median OS was 18.9 months (95% CI, 10.8 to not reached), with the median follow-up duration of 22.0 months (range, 12.0–23.7). The estimated 12-month OS rate was 67.2% (95% CI, 49.4 to 79.9). The most common ≥grade 3 treatment-related adverse events were hypertension (32.4%), decreased neutrophil count (29.7%) and decreased platelet count (13.5%). One (2.7%) patient died of grade 5 hemorrhage that was judged possibly related to study treatment by investigator. Conclusion The camrelizumab with famitinib combination appeared to show antitumor activity in heavily pretreated patients with platinum-resistant ROC with an acceptable safety profile. This combination might provide a novel alternative treatment strategy in platinum-resistant ROC setting and warranted further exploration. Trial registration number NCT03827837 .
THE GERMAN REVOLT AGAINST CONTRACT PRACTICE.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Foodborne Outbreak of Diarrheal Illness Associated With Cryptosporidium parvum—Minnesota, 1995
Journal: JAMA (1996)

On September 29, 1995, the Minnesota Department of Health (MDH) received reports of acute gastroenteritis among an estimated 50 attendees of a social event in Blue Earth County on September 16. This report summarizes the epidemiologic and laboratory investigations of the outbreak, which indicate the probable cause for this foodborne outbreak was Cryptosporidium parvum.
Screening for Chronic Obstructive Pulmonary Disease
Authors: Barbara P. Yawn, Nancy K. Leidy, Fernando Martinez
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Privacy, epidemiology, and record linkage.
Journal: BMJ (1979)

streptokinase in clearing pulmonary emboli, it is surprising that the group do not discuss the possibility that an effect on venous thromboembolism might account for their haemodynamic findings and for part of the favourable effect on mortality.Finally, there was a definite and inexplicable difference in the size of the heart at six months between the groups, fewer of the patients given lytic treatment having enlargement of the heart.The study group is to be commended for its ability to mount such a trial, but the low randomisation rate, the uncertainty about the comparability of the two groups, and the clinical and laboratory complexities inherent in any effective and well-controlled lytic regimen will limit the practical impact of the study on doctors caring for patients with acute infarction.If, however, the mechanisms which underlie the apparent effect of streptokinase on mortalityand especially on late mortality-can be discovered and can be produced by less demanding regimens, then a real advance will have been made.
From the Food and Drug Administration
Authors: S. L. Nightingale
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Osteopontin targeted theranostic nanoprobes for laser-induced synergistic regression of vulnerable atherosclerotic plaques
Authors: Mengqi Xu, Cong Mao, Haoting Chen, Lu Liu, Yabin Wang, Abid Hussain, Sulei Li, Xu Zhang, Ruslan G. Tuguntaev, Xing-Jie Liang, Weisheng Guo, Feng Cao
Journal: Acta Pharmaceutica Sinica B (2021)

Vulnerable atherosclerotic plaque (VASPs) is the major pathological cause of acute cardiovascular event. Early detection and precise intervention of VASP hold great clinical significance, yet remain a major challenge. Photodynamic therapy (PDT) realizes potent ablation efficacy under precise manipulation of laser irradiation. In this study, we constructed theranostic nanoprobes (NPs), which could precisely regress VASPs through a cascade of synergistic events triggered by local irradiation of lasers under the guidance of fluorescence/MR imaging. The NPs were formulated from human serum albumin (HSA) conjugated with a high affinity-peptide targeting osteopontin (OPN) and encapsulated with photosensitizer IR780 and hypoxia-activatable tirapazamine (TPZ). After intravenous injection into atherosclerotic mice, the OPN-targeted NPs demonstrated high specific accumulation in VASPs due to the overexpression of OPN in activated foamy macrophages in the carotid artery. Under the visible guidance of fluorescence and MR dual-model imaging, the precise near-infrared (NIR) laser irradiation generated massive reactive oxygen species (ROS), which resulted in efficient plaque ablation and amplified hypoxia within VASPs. In response to the elevated hypoxia, the initially inactive TPZ was successively boosted to present potent biological suppression of foamy macrophages. After therapeutic administration of the NPs for 2 weeks, the plaque area and the degree of carotid artery stenosis were markedly reduced. Furthermore, the formulated NPs displayed excellent biocompatibility. In conclusion, the developed HSA-based NPs demonstrated appreciable specific identification ability of VASPs and realized precise synergistic regression of atherosclerosis.
Pulsatile flow profiles modulate MCP-1 expression in Ox-PAPC treated endothelial cells Tzung K. Hsiai, Sung K. Cho, Susan Hama, Henry Honda, Srinivasa Reddy, Mohamad Navab, Judith Berliner, Linda Demer, Alan M. Fogelman, Chih M. Ho. UCLA School of Medicine, Los Angeles, CA, UCLA School of Engineering &amp; Applied Sciences, Los Angeles, CA
Journal: Journal of the American College of Cardiology (2001)
Elimination of cardiopulmonary bypass improves early clinical outcome after coronary artery bypass surgery in patients with chronic renal insufficiency Sotiris C. Stamou, Michael Mack, Syma Prince, Albert J. Pfister, Mercedes K.C. Dullum, Paul J. Corso. Washington Hospital Center, Washington, DC, Medical City Dallas Hospital, Dallas, TX
Journal: Journal of the American College of Cardiology (2001)
Early-onset pancreatic cancer: Defining contemporary presentation, treatment, and outcomes in the under 50 age group using real-world data.
Authors: Shehara Ramyalini Mendis, Lara Rachel Lipton, Sumitra Ananda, Michael Michael, Sue-Anne McLachlan, Benjamin N. Thomson, Brett Knowles, Adrian Fox, Mehrdad Nikfarjam, Val Usatoff, Julia Shapiro, Kate Clarke, Sharon Tracy Pattison, Cheng Ean Chee, Rob Zielinski, Rachel Wong, Peter Gibbs, Belinda Lee
Journal: Journal of Clinical Oncology (2022)

533 Background: The incidence of pancreatic cancer is increasing in younger patients (pts). Early onset pancreatic cancer (EOPC) is reportedly diagnosed at a later stage, potentially compromising outcomes compared to later onset pts (LOPC). With recent gains in staging and neo/adjuvant regimens, we sought to elaborate on the characteristics of EOPC and LOPC in a contemporary real-world cohort. Methods: The PURPLE registry, a prospectively collected multi-site data set on consecutive pancreatic cancer pts was interrogated. Patient, tumor, treatment and outcome data were extracted for EOPC vs LOPC. EOPC were those diagnosed prior to age 50 and LOPC after age 50. Resectability status was per MDT consensus. Results: Of 1534 pts, 93 (6%) were EOPC (51% male) and 1442 (94%) LOPC (51% male). EOPC had better ECOG performance status (0-1: 95% vs 81%, Relative Risk [RR] 1.2, p &lt; 0.001) and Charlson Comorbidity Index Score (0-2: 98% vs 28%, RR 3.5, p &lt; 0.001). Primary tumor site (head/body/tail: 66%/11%/20% for EOPC and 68%/17%/14% for LOPC), and staging (resectable/borderline resectable/locally advanced/metastatic: 29%/16%/14%/41% for EOPC vs 28%/9%/21%/41% for LOPC) did not differ. 25 (93%) of EOPC and 320 (79%) LOPC resectable pts underwent resection (p = 0.13). 12 (80%) EOPC and 36 (26%) LOPC borderline resectable pts underwent resection (RR 3.0, p &lt; 0.001). Resection margin status (R0 vs R1 vs R2) did not differ. Resected EOPC more frequently received neoadjuvant therapy (30% vs 9%, RR 3.2, p = 0.001). EOPC were more likely to receive palliative chemotherapy in the advanced/metastatic setting (77% vs 49%, RR 1.6, p &lt; 0.001), and were more likely to receive first line (1L) FOLFIRINOX than gemcitabine-nab-paclitaxel (36% vs 18%, RR 2, p = 0.019). Median overall survival (OS) was superior for EOPC (24 vs 12 months, Hazard Ratio [HR] 0.55, p &lt; 0.001). For resectable pts, relapse free survival (RFS) did not differ but OS was superior for EOPC (undefined vs 27.7 months, HR 0.26, p = 0.004). In borderline resectable pts, RFS was similar and OS only numerically superior for EOPC (31.2 vs 17.7 months, p = 0.20). For locally advanced disease, 1L progression free survival (PFS1) was similar and OS was superior for EOPC (27.8 vs 11 months, HR 0.40, p = 0.008). There was no difference in PFS1/OS for metastatic pts. Conclusions: EOPC are fitter, with similar stage at diagnosis as LOPC. EOPC are more likely to receive neoadjuvant chemotherapy and undergo resection when presenting with borderline resectable disease. EOPC receive more treatment and have superior OS, with RFS/PFS1 not statistically different to LOPC.
Correction to: A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers
Authors: Tonći Šuštić, Sake van Wageningen, Evert Bosdriesz, Robert J. D. Reid, John Dittmar, Cor Lieftink, Roderick L. Beijersbergen, Lodewyk F. A. Wessels, Rodney Rothstein, René Bernards
Journal: Genome Medicine (2021)

An amendment to this paper has been published and can be accessed via the original article.
Abstract P148: Heart Disease Among Breast Cancer Patients
Authors: Tekeda F Ferguson, Sunayana Kumar, Denise Danos
Journal: Circulation (2018)

Purpose: In conjunction with women being diagnosed earlier with breast cancer and a rapidly aging population, advances in cancer therapies have swiftly propelled cardiotoxicity as a major health concern for breast cancer patients. Frequent cardiotoxicity outcomes include: reduced left ventricular ejection fraction (LVEF), myocardial infarction, asymptomatic or hospitalized heart failure, arrhythmias, hypertension, and thromboembolism. The purpose of this study was to use an electronic health records system determine if an increased odds of heart disease was present among women with breast cancer. Methods: Data from the Research Action for Health Network (REACHnet) was used for the analysis. REACHnet is a clinical data research network that uses the common data model to extract electronic health records (EHR) from health networks in Louisiana (n=100,000).Women over the age of 30 with data (n=35,455) were included in the analysis. ICD-9 diagnosis codes were used to classify heart disease (HD) (Hypertensive HD, Ischemic HD, Pulmonary HD, and Other HD) and identify breast cancer patients. Additional EHR variables considered were smoking status, and patient vitals. Chi-square tests, crude, and adjusted logistic regression models were computed utilizing SAS 9.4. Results: Utilizing diagnoses codes our study team has estimated 28.6% of women over the age of 30 with a breast cancer diagnosis (n=816) also had a heart disease diagnosis, contrasted with 15.6% of women without a breast cancer diagnosis. Among patients with heart disease, there was no significant difference in the distribution of the type of heart disease diagnoses by breast cancer status (p=0.87). There was a 2.21 (1.89, 2.58) crude odds ratio of having a CVD diagnoses among breast cancer cases when referenced to cancer free women. After adjusting for age (30-49, 50-64, 65+), race (black/white), and comorbidities (obesity/overweight, diabetes, current smoker) there was an increased risk of heart disease (OR: 1.24 (1.05, 1.47)). Conclusion: The short-term and long-term consequences of cardiotoxicity on cancer treatment risk-to-benefit ratio, survivorship issues, and competing causes of mortality are increasingly being acknowledged. Our next efforts will include making advances in predictive risk modeling. Maximizing benefits while reducing cardiac risks needs to become a priority in oncologic management and monitoring for late-term toxic effects.